© 2021 BioMarin. All rights reserved.

BioMarin Announces Date and Time Change of Fourth Quarter and Full Year 2006 Financial Results Conference Call and Webcast to Tuesday, February 20 at 11:00 a.m. ET (17:00 CET)
Feb 16, 2007
NOVATO, Calif.

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has changed the date and time of its fourth quarter and full year 2006 financial results conference call and webcast from Thursday, February 22 at 5:00 p.m. ET (23:00 CET) to Tuesday, February 20, at 11:00 a.m. ET (17:00 CET).

  What: BioMarin Fourth Quarter and Full Year 2006 Earnings Call and Webcast
  When: Tuesday, February 20, 2007 at 11:00 a.m. ET (17:00 CET)
  U.S. / Canada Dial-in Number:  800.901.5217
  International Dial-in Number:  617.786.2964
  Participant Code: 35915200
  Replay Dial-in Number: 888.286.8010
  Replay International Dial-in Number: 617.801.6888
  Replay Code: 94899251

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension and peripheral arterial disease. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

  Naglazyme(R) is a registered trademark of BioMarin Pharmaceutical Inc.
  Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.


  Investors and Media
  Eugenia Shen
  BioMarin Pharmaceutical Inc.

First Call Analyst:
FCMN Contact: eshen@bmrn.com

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Eugenia Shen of BioMarin Pharmaceutical Inc., +1-415-506-6570